The company plans to announce Phase 1b interim data by mid-2026, and the TENACITY-01 study is expected to be completed by late 2028. This timing enables progression to Phase 2 evaluation following ...
A new study published in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center ...
News-Medical.Net on MSN
Study reveals a therapeutic vulnerability in aggressive subtype of triple-negative breast cancer
A new study published today in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer ...
Rb1 loss may serve as a predictive biomarker to guide new targeted therapies for select breast cancers resistant to standard ...
Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ...
The anti-CD40 antibody tegoprubart offers a tacrolimus-free immunosuppression option for preventing islet transplant ...
ASH 2025 highlighted innovative cancer treatments, including in vivo CAR T therapy and options that enhance quality of life ...
The satellite-tagged Olive Ridley turtle ‘Dhaval Lakshmi’ that was released into the water at Dahanu coast in Maharashtra’s ...
A fatty diet doesn’t just damage the liver — it rewires its cells in ways that give cancer a dangerous head start.
A microscopic flaw in the brain’s cellular scaffolding can shape brain size for life.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback